Due to the enormous economic, health, and social costs of the COVID-19 pandemic, there are high expected social returns to investing in parallel in multiple approaches to accelerating vaccination. We argue there are high expected social returns to investigating the scope for lowering the dosage of some COVID-19 vaccines. While existing evidence is not dispositive, available clinical data on the immunogenicity of lower doses combined with evidence of a high correlation between neutralizing antibody response and vaccine efficacy suggests that half or even quarter doses of some vaccines could generate high levels of protection, particularly against severe disease and death, while potentially expanding supply by 450 million to 1.55 billion doses per month, based on supply projections for 2021. An epidemiological model suggests that, even if fractional doses are less effective than standard doses, vaccinating more people faster could substantially reduce total infections and deaths. The costs of further testing alternative doses are much lower than the expected public health and economic benefits. However, commercial incentives to generate evidence on fractional dosing are weak, suggesting that testing may not occur without public investment. Governments could support either experimental or observational evaluations of fractional dosing, for either primary or booster shots. Discussions with researchers and government officials in multiple countries where vaccines are scarce suggests strong interest in these approaches.

More on this topic

BFI Working Paper·Mar 11, 2024

Fallow Lengths and the Structure of Property Rights

Etienne Le Rossignol, Sara Lowes and Eduardo Montero
Topics: Development Economics
BFI Working Paper·Feb 2, 2024

Fiscal Rules, Austerity in Public Administration, and Political Accountability: Evidence from a Natural Experiment in Colombia

Maria Carreri and Luis Martínez
Topics: Development Economics, Monetary Policy
BFI Working Paper·Jan 30, 2024

Digital Information Provision and Behavior Change: Lessons from Six Experiments in East Africa

Raissa Fabregas, Michael Kremer, Matthew Lowes, Robert On and Giulia Zane
Topics: Development Economics, Technology & Innovation